title: CD20-targeting in B-cell malignancies: novel prospects for antibodies and combination therapies.
abstract: Expression of CD20 antigen by the most of transformed B cells is believed to be the driving force for targeting this molecule by using anti-CD20 monoclonal antibodies. While it is true that most lymphoma/leukemia patients can be cured, these regimens are limited by the emergence of treatment resistance. Based on these observations, development of anti-CD20 monoclonal antibodies and combination therapies have been recently proposed, in particular with the aim to optimize the cytotoxic activity. Here we outline a range of new experimental agents concerning the CD20 positive B-cell tumors which provide high benefit from conventional therapy.
authors.affiliation: Cellular and Molecular Research Center, Taleghani Children Hospital, Gorgan University of Medical Sciences, Gorgan, Iran.|Department of Biotechnology, Faculty of Advanced Medical Technologies, Golestan University of Medical Sciences, Gorgan, Iran.
authors.forename: Yaghoub
authors.initials: Y
authors.lastname: Safdari
authors.affiliation: Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. vahideh_ahmadzadeh@yahoo.com.
authors.forename: Vahideh
authors.initials: V
authors.lastname: Ahmadzadeh
authors.affiliation: Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.|Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
authors.forename: Safar
authors.initials: S
authors.lastname: Farajnia
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D018951:Antigens, CD20 / Q000235:genetics / Q000276:immunology* / Q000378:metabolism; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001402:B-Lymphocytes / Q000187:drug effects; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000628:therapy*
chemical_list: D000911:Antibodies, Monoclonal; D018951:Antigens, CD20
keywords: Antibody-based therapeutics; B-cell malignancies; CD20 antigen; Combination therapy